Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

AI-Based Video Analysis for Motor Development Assessment in Children

NCT07597356 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-01-01
Last updated
2026-05-19

Condition(s) studied

Motor Development AssessmentArtificial Intelligence-Based Movement Analysis

Investigational drug(s) / intervention(s)

Observational Assessment Only

Observational Assessment Only: This study does not include any therapeutic or experimental intervention. The procedures are limited to observational assessment and data collection. Participants perform standardized motor tasks and are video recorded under controlled conditions. No treatment, training, or behavioral modification is applied. The collected data are analyzed using artificial intelligence-based methods to evaluate motor development patterns.

Study summary

This is a non-interventional, prospective observational study aimed at developing and validating an artificial intelligence-based system for assessing motor development in children using video analysis. Children aged 5 to 10 years will perform standardized motor tasks, which will be recorded under controlled conditions. The recorded videos will be analyzed using computer vision and deep learning techniques to extract movement patterns.

The results of the AI-based analysis will be compared with standardized motor assessment scores obtained from the Bruininks-Oseretsky Test of Motor Proficiency, Second Edition - Short Form (BOT-2 SF). Participants will be classified into typical and atypical motor development groups based on BOT-2 scores. The primary objective is to evaluate the classification performance of the AI model. Secondary analyses will examine the relationship between AI predictions and continuous motor performance scores.

The study is designed to explore whether motor development can be assessed objectively without direct clinical testing, using only short video recordings. The findings may contribute to the development of scalable and accessible digital screening tools for early identification of motor development differences in children.

Eligibility

Sex
ALL
Min age
5 Years
Max age
10 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Children aged between 5 and 10 years * No diagnosed neurological, developmental, or orthopedic disorders * Ability to follow verbal instructions * Informed consent obtained from parents or legal guardians * No prior participation in sensory integration therapy or special education programs Exclusion Criteria: * Diagnosed neurological, developmental, or orthopedic conditions (e.g., autism spectrum disorder, cerebral palsy, epilepsy) * Visual or hearing impairments affecting task performance * Severe attention or behavioral problems preventing test completion * Physical limitations preventing participation in motor tasks

Primary outcome measure(s)

  • AI-Based Classification Accuracy of Motor Development — Baseline assessment (Day 1)
    Classification accuracy of the artificial intelligence model in distinguishing typical versus atypical motor development based on video analysis, using the Bruininks-Oseretsky Test of Motor Proficiency, Second Edition Short Form (BOT-2 SF) total score as the reference standard. BOT-2 SF scores range from 0 to 88, with higher scores indicating better motor proficiency.

Trial sites (1)

FacilityCityRegionStatus
Istanbul Medipol University Istanbul Beykoz Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07597356 on ClinicalTrials.gov ↗ ← All trials in Turkey